Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-11-25 | Kate Beebe DeVarney, Ph.D. (59) joined Titan in February 2007 and has served as our President and Chief Operating Officer since October 2020. Prior thereto, she served as Chief Scientific Officer. She has been a member of the Board since December 2019. Based on Dr. Beebe DeVarney’s extensive knowledge of our product development programs, our Board believes that Dr. Beebe DeVarney has the appropriate set of skills to serve as member of the Board. |
| 2021-11-05 | Katherine Beebe DeVarney, Ph.D. (60) joined Titan in February 2007 and currently serves as our President and Chief Operating Officer. She has been a member of the Board since December 2019. ... Based on Dr. Beebe DeVarney’s extensive knowledge of the medical, research, and regulatory requirements of product development programs, our Board believes that Dr. Beebe DeVarney has the appropriate set of skills to serve as member of the Board. |
| 2023-11-28 | Dr. Beebe DeVarney is our President and Chief Operating Officer and a member of the Board. The shares of common stock beneficially owned include (i) 306,533 shares of common stock subject to options exercisable within 60 days of November 17, 2023 with a weighted average exercise price of $3.49 and (ii) 66,250 shares of common stock issuable pursuant to unreleased stock awards. |
Data sourced from SEC filings. Last updated: 2026-02-03